Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 19.10.2026 1 Abdom Radiol (NY) 2 Adv Sci (Weinh) 1 Am J Surg Pathol 1 Apoptosis 3 Arch Esp Urol 1 Arh Hig Rada Toksikol 1 Asia Pac J Clin Oncol 1 Asian J Endosc Surg 1 Beijing Da Xue Xue Bao Yi Xue Ban 1 Biochim Biophys Acta Mol Basis Dis 1 Biomed Pharmacother 4 BJU Int 1 Cancer Cell 1 Cancer Cell Int 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Genet 1 Cancer Med 2 Cancers (Basel) 1 Cell Signal 1 Clin Chem Lab Med 1 Clin Radiol 1 Colloids Surf B Biointerfaces 1 Crit Rev Oncol Hematol 1 Eur J Radiol 1 Eur Urol Focus 2 Front Immunol 1 Front Med (Lausanne) 1 Front Oncol 1 Immunotherapy 1 Insights Imaging 2 Int J Mol Sci 1 Int J Pharm 2 Int J Urol 1 J Cancer Res Clin Oncol 1 J Med Imaging Radiat Oncol 1 J Transl Med 1 Med Care 1 Mol Biol Rep 1 Nat Rev Urol 1 Neoplasia 3 Nihon Hinyokika Gakkai Zasshi 1 Nutrients 1 Oncol Lett 1 Pathobiology 1 Phytomedicine 1 Quant Imaging Med Surg 1 Scand J Urol 1 Sci China Life Sci 2 Transl Androl Urol 1 Transl Oncol 6 Urol Oncol 1 Urology 1 Xenotransplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Abdom Radiol (NY)

1. HAN Y, She Y, Wei J, Zhang X, et al
   Clinical indicators combined with spectral CT in differentiating non-muscle-invasive bladder urothelial carcinoma from cystitis glandularis.
   Abdom Radiol (NY). 2026;51:5939-5949.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

2. LIU X, Shi ZD, Wang GC, Wang JM, et al
   Serial H&E Pathology Reveals Progression-Associated Nuclear Size Drift as a Longitudinal Digital Readout of Bladder Cancer Evolution.
   Adv Sci (Weinh). 2026 Oct 14:e78299. doi: 10.1002/advs.78299.
   PubMed         Abstract available
   
   
3. XIONG S, Li G, Wu Y, Liang Y, et al
   UCtracker: A Deep Learning-Based DNA Methylation Model for Noninvasive Diagnosis and Recurrence Surveillance of Urothelial Carcinoma in a Prospective Study.
   Adv Sci (Weinh). 2026;13:e76710.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

4. LI H, Bhardwaj S, Feng M, McNamara M, et al
   Lipid-Rich Urothelial Carcinoma: A Contemporary Clinicopathologic Study of 40 Patients With Transcriptional Tumor Profiling.
   Am J Surg Pathol. 2026;50:1269-1280.
   PubMed         Abstract available
   
   

   
   Apoptosis

5. SINGH A, Jain P
   CAF-derived GLG1 drives bladder cancer growth and apoptosis resistance.
   Apoptosis. 2026;31:247.
   PubMed        
   
   

   
   Arch Esp Urol

6. LI G, Cui J, Feng X, Li W, et al
   Single-Cell-Informed Characterization of A Candidate S100A9-Associated Epithelial Program and Prognostic Signature in Bladder Cancer.
   Arch Esp Urol. 2026;79:1381-1394.
   PubMed         Abstract available
   
   
7. TENG H, Chen J, Qian J, Chen L, et al
   Metabolic Syndrome and Bladder Cancer Risk: A Meta-Analysis of Cohort Studies.
   Arch Esp Urol. 2026;79:1419-1428.
   PubMed         Abstract available
   
   
8. HAN S, Li X, Ma L, Hu Z, et al
   Real-World Comparative Effectiveness of Lobaplatin Versus Epirubicin and Gemcitabine for Post-TURBT Intravesical Therapy in Non-Muscle-Invasive Bladder Cancer.
   Arch Esp Urol. 2026;79:1440-1449.
   PubMed         Abstract available
   
   

   
   Arh Hig Rada Toksikol

9. TURKOVIC AH, Stanecic Z, Butorac A, Kasuba V, et al
   Synergistic effects of combined exposure to hydroquinone and nitrofurantoin in T24 bladder cells: an in vitro toxicology study with implications for risk assessment.
   Arh Hig Rada Toksikol. 2026;77:169-181.
   PubMed         Abstract available
   
   

   
   Asia Pac J Clin Oncol

10. HAYNE D, Sengupta S, Zhang AY, Oliveira N, et al
    Australian Practical Guide on the Management of Muscle-Invasive Bladder Cancer.
    Asia Pac J Clin Oncol. 2026 Oct 9. doi: 10.1111/ajco.70207.
    PubMed         Abstract available
    
    

    
    Asian J Endosc Surg

11. SATO T, Hayata N, Miura T, Mishina M, et al
    Feasibility of Laparoscopic Partial Cystectomy for Bladder Paraganglioma: A Four-Case Series.
    Asian J Endosc Surg. 2026;19:e70394.
    PubMed         Abstract available
    
    

    
    Beijing Da Xue Xue Bao Yi Xue Ban

12. YANG H, Zhang R, Zhang Z, Zhao K, et al
    [Conversion from Bricker to orthotopic neobladder: A case report].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:1095-1098.
    PubMed         Abstract available
    
    

    
    Biochim Biophys Acta Mol Basis Dis

13. WIGNER-JEZIORSKA P, Grebowski R, Tokarz P, Plazuk D, et al
    Purine and citrate metabolism in urolithiasis and bladder cancer: An integrated genetic, gene-expression, and targeted metabolite analysis.
    Biochim Biophys Acta Mol Basis Dis. 2026 Oct 14:168500.
    PubMed         Abstract available
    
    

    
    Biomed Pharmacother

14. MCFARLANE L, Dugbartey GJ, McLeod P, Shamma T, et al
    Evaluation of hydrogen sulfide inhibition as an adjunct to gemcitabine and BCG therapy in non-muscle-invasive bladder cancer.
    Biomed Pharmacother. 2026;204:119983.
    PubMed         Abstract available
    
    

    
    BJU Int

15. WANG J, Zhao Y, Ye Y, Qi X, et al
    Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence.
    BJU Int. 2026 Oct 11. doi: 10.1111/bju.70488.
    PubMed         Abstract available
    
    
16. MELLE-HANNAH M, Kjolhede H, Backdahl H, Johansson ME, et al
    First-in-human outpatient management of recurrent NMIBC with the Multi4 instrument.
    BJU Int. 2026;138:867-876.
    PubMed         Abstract available
    
    
17. MUNK L, Hyldgaard JM, Kumasegaram V, Milling RV, et al
    Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial.
    BJU Int. 2026;138:831-840.
    PubMed         Abstract available
    
    
18. LEHNER F, Dugas S, Birkhauser V, Gross O, et al
    Bladder washing cytology in the initial evaluation of patients with neuro-urological disorders: to do or not to do?
    BJU Int. 2026;138:860-866.
    PubMed         Abstract available
    
    

    
    Cancer Cell

19. WANG Y, Chen Z, Liu Z, Ma Z, et al
    Tumor cells recruit macrophage bodyguards to outlast chemotherapy.
    Cancer Cell. 2026;44:1930-1932.
    PubMed         Abstract available
    
    

    
    Cancer Cell Int

20. ZHONG X, Wang G, Zhang H, Shi Y, et al
    Bladder cancer organoids in precision medicine: bridging basic science, clinical therapeutics and drug development.
    Cancer Cell Int. 2026;26:340.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

21. HAN M, Park JH, Hong JY, Han K, et al
    Joint Associations of Abdominal Obesity, General Obesity, and Smoking with Bladder Cancer Risk Among Postmenopausal Women: A Nationwide Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    

    
    Cancer Genet

22. LI Y, Li X, Jiang L, Sun L, et al
    Urinary cell TWIST1 methylation as a non-invasive dual biomarker: A Multicenter study for early detection and recurrence monitoring in bladder cancer.
    Cancer Genet. 2026;308-309:203-211.
    PubMed         Abstract available
    
    

    
    Cancer Med

23. MOCHIZUKI T, Kawahara T, Hashizume A, Yamazaki M, et al
    Changes in the Age Distribution of Radical Prostatectomy and Radical Cystectomy During the Diffusion of Robot-Assisted Surgery in Japan.
    Cancer Med. 2026;15:e72370.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

24. LI S, Li M, Zhang Y, Pu J, et al
    Metabolic Reprogramming in Bladder Cancer: Molecular Drivers, Immune Regulation and Therapeutic Opportunities.
    Cancers (Basel). 2026;18:3202.
    PubMed         Abstract available
    
    
25. WANG Z, Afshar N, Hodge AM, Jayasekara H, et al
    Consumption of Processed Meat and Unprocessed Red Meat and Risk of Bladder Cancer: A Pooled Analysis of 30 Cohort Studies.
    Cancers (Basel). 2026;18:3203.
    PubMed         Abstract available
    
    

    
    Cell Signal

26. DONG X, Li Y, Yan Y, Xiong H, et al
    A cytoplasmic cis-acting circuit confines PI3K/AKT-driven lineage plasticity in bladder cancer.
    Cell Signal. 2026 Oct 16:112952. doi: 10.1016/j.cellsig.2026.112952.
    PubMed         Abstract available
    
    

    
    Clin Chem Lab Med

27. OKUYAMA R, Horiuchi H, Nakamura M, Muroya M, et al
    Enhanced detection of bladder cancer using machine learning analysis of routine urinary sediment data.
    Clin Chem Lab Med. 2026 Oct 19. doi: 10.1515/cclm-2026-1514.
    PubMed         Abstract available
    
    

    
    Clin Radiol

28. WANG Z, Jiang H, Hu C, Zhang H, et al
    MRI morphometric features and apparent diffusion coefficients predict muscle invasion in VI-RADS 3 bladder cancers.
    Clin Radiol. 2025;103:107206.
    PubMed         Abstract available
    
    

    
    Colloids Surf B Biointerfaces

29. LOKE YL, Lim XY, Beishenaliev A, Goh SJ, et al
    Ultrasound-controlled therapeutics for bladder cancer: Mechanisms, recent advances, and future perspectives.
    Colloids Surf B Biointerfaces. 2026;270:116248.
    PubMed         Abstract available
    
    

    
    Crit Rev Oncol Hematol

30. MOLLICA V, Rosellini M, Giannatempo P, Gupta S, et al
    Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trials.
    Crit Rev Oncol Hematol. 2026;228:105648.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

31. FUKUI K, Kobayashi M, Yoshida S, Arita Y, et al
    Diagnostic performance of post-chemoradiotherapy nacVI-RADS for identifying pathological complete response in muscle-invasive bladder cancer.
    Eur J Radiol. 2026;206:113292.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

32. TAN YG, Dudinec J, Kamat AM, Lim BJH, et al
    Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study.
    Eur Urol Focus. 2026 Oct 13:S2405-4569(26)00221.
    PubMed         Abstract available
    
    

    
    Front Immunol

33. LU J, Jiang Y, Jin Y, Zhang Y, et al
    Tumor-intrinsic execution of interferon-gamma-associated immunity in bladder cancer: checkpoints in signaling, recruitment, and recognition.
    Front Immunol. 2026;17:1979524.
    PubMed         Abstract available
    
    
34. RAO XP, Zou XC, Liu X, Xu LY, et al
    Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.
    Front Immunol. 2026;17:1891151.
    PubMed         Abstract available
    
    

    
    Front Med (Lausanne)

35. SAHINI H, Anzengruber M, Lachelt U
    Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.
    Front Med (Lausanne). 2026;13:1979620.
    PubMed         Abstract available
    
    

    
    Front Oncol

36. ATIF K, Arif U, Gorish MA, Saleem SM, et al
    National trends and disparities in mortality involving bladder cancer and substance use disorders in the United States, 1999-2023.
    Front Oncol. 2026;16:1883338.
    PubMed         Abstract available
    
    

    
    Immunotherapy

37. KAPAR C, Ozkan O, Eylemer Mocan E, Yaslikaya S, et al
    Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.
    Immunotherapy. 2026;18.
    PubMed         Abstract available
    
    

    
    Insights Imaging

38. GREIDANUS J, Bernabei C, Chupetvloska K, Agrotis G, et al
    Reproducibility and diagnostic performance of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: a multi-ROI comparison analysis from the phase-Ib NABUCCO trial.
    Insights Imaging. 2026;17:255.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

39. MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
    FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2026;27:8698.
    PubMed         Abstract available
    
    
40. ANDREU-INGLES M, Onoiu AI, Grifoll-Escoda M, Hernandez-Aguilera A, et al
    Urinary DNA Methylation Profiling Identifies a Biologically Distinct Subgroup of Low-Grade Urothelial Carcinoma with High-Grade-Associated Features.
    Int J Mol Sci. 2026;27:8934.
    PubMed         Abstract available
    
    

    
    Int J Pharm

41. GAO J, Murray BO, Wu Q, Fryer MT, et al
    Evaluation of a rapid-release mitomycin C-loaded porous microcapsule formulation (MitoCap) in a human urothelium-tumour model.
    Int J Pharm. 2026;704:127429.
    PubMed         Abstract available
    
    

    
    Int J Urol

42. ZENG D, Li J
    From Biofluid Detectability to Bladder-Cancer-Specific Validation: Interpreting CTSV as a Noninvasive Biomarker.
    Int J Urol. 2026;33:e70650.
    PubMed        
    
    
43. HASHIMOTO M, Tomiyama E, Inoki L, Miki K, et al
    Urinary Extracellular Vesicle-Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer.
    Int J Urol. 2026;33:e70656.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

44. DINKEL H, Seifert KE, Bogemann M, Schrader AJ, et al
    Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literature.
    J Cancer Res Clin Oncol. 2026;152:197.
    PubMed         Abstract available
    
    

    
    J Med Imaging Radiat Oncol

45. CHAI JL, Lan Z, Svystun O, Shaikh MJ, et al
    MR Imaging and Radiomics Features for Predicting Variant Histology of Bladder Cancer: A Single Centre Retrospective Analysis.
    J Med Imaging Radiat Oncol. 2026 Oct 14. doi: 10.1111/1754-9485.70193.
    PubMed         Abstract available
    
    

    
    J Transl Med

46. CHEN C, Yang Y, Chen Z, Li X, et al
    Liquid biopsy in bladder cancer: towards precision oncology.
    J Transl Med. 2026;24:1294.
    PubMed         Abstract available
    
    

    
    Med Care

47. HONG YD, Enewold L, Zeruto CA, Mariotto AB, et al
    Receipt of Cancer Surgery: A Comparison of Cancer Registry Data and Medicare Claims.
    Med Care. 2026;64:787-792.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

48. SULHAN H, Akkoc Y, Akgollu E
    CYP24A1 rs1570669 and rs2762934 polymorphisms and bladder cancer susceptibility: a Turkish case-control study.
    Mol Biol Rep. 2026;53:1700.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

49. DANESHMAND S, Boorjian SA, Meeks JJ, Lotan Y, et al
    Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies.
    Nat Rev Urol. 2026 Oct 15. doi: 10.1038/s41585-026-01193.
    PubMed         Abstract available
    
    

    
    Neoplasia

50. HUANG Z, Liu B, Li X, Jin C, et al
    Corrigendum to "RUNX2 enhances bladder cancer progression by promoting glutamine metabolism" [Neoplasia 60 (2025) 101120, doi: 10.1016/j.neo.2024.101120].
    Neoplasia. 2026;82:101373.
    PubMed        
    
    

    
    Nihon Hinyokika Gakkai Zasshi

51. IKAI T, Shirane H, Yoshioka H, Akiyama K, et al
    [A CASE OF MALIGNANCY ARISING IN A NEOBLADDER MORE THAN 50 YEARS AFTER RECONSTRUCTION].
    Nihon Hinyokika Gakkai Zasshi. 2026;117:83-86.
    PubMed         Abstract available
    
    
52. SAKURA Y, Yamashita R, Ito K, Shinsaka H, et al
    [CORRELATION BETWEEN RELATIVE DOSE INTENSITY AND TREATMENT OUTCOMES OF ENFORTUMAB VEDOTIN IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC UROTHELIAL CARCINOMA].
    Nihon Hinyokika Gakkai Zasshi. 2026;117:1-8.
    PubMed         Abstract available
    
    
53. YAMAGUCHI M, Ide H, Kitaoka S, Nishimura C, et al
    [UROTHELIAL CARCINOMA WITH SARCOMATOID SUBTYPE OF THE BLADDER ACCOMPANIED BY TROUSSEAU'S SYNDROME: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2026;117:16-19.
    PubMed         Abstract available
    
    

    
    Nutrients

54. WU YW, Yu EY, Chen YT, Li MH, et al
    Soy Consumption and the Risk of Developing Bladder Cancer: A Pooled Analysis of Cohort Studies from the International Pooled Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study.
    Nutrients. 2026;18:3110.
    PubMed         Abstract available
    
    

    
    Oncol Lett

55. CHEN X, Liu S, Zhang X, Chen X, et al
    KRT14 activated by transcription factor E2F1 promotes bladder cancer progression.
    Oncol Lett. 2026;32:529.
    PubMed         Abstract available
    
    

    
    Pathobiology

56. SHI Y, Zong X, Lian J, Wang Y, et al
    Nectin-4 and TROP-2 in bladder cancer: biomarkers for targeted therapy.
    Pathobiology. 2026 Oct 15:1. doi: 10.1159.
    PubMed         Abstract available
    
    

    
    Phytomedicine

57. LI K, You G, Liu Z, Cheng X, et al
    Artemisitene targets GLIS3 to inhibit the NF-kappaB-TNF signaling pathway and suppress bladder cancer cell growth.
    Phytomedicine. 2026;162:158853.
    PubMed         Abstract available
    
    

    
    Quant Imaging Med Surg

58. WANG D, Zhang Z, Wang Y, Wang Z, et al
    Interobserver agreement of non-parallel transmission technology zoomed-diffusion-weighted imaging (DWI) for ordinal biparametric Vesical Imaging-Reporting and Data System (VI-RADS)-based scoring in bladder cancer lesions >/=1 cm.
    Quant Imaging Med Surg. 2026;16:801.
    PubMed         Abstract available
    
    

    
    Scand J Urol

59. LIEDBERG F, Bobjer J, Hagberg O, Aljabery F, et al
    Lower proportion of bladder cancer diagnosed at unscheduled hospitalization after introduction of standardized care pathways in Sweden.
    Scand J Urol. 2026;61:241-246.
    PubMed         Abstract available
    
    

    
    Sci China Life Sci

60. SHANG H, Yu S, Zhou Z, Wang D, et al
    pH-responsive biomimetic liposomes enhance targeted immunotherapy of bladder cancer.
    Sci China Life Sci. 2026 Oct 12. doi: 10.1007/s11427-026-3557.
    PubMed         Abstract available
    
    

    
    Transl Androl Urol

61. LI B, Ji G, Wang W, Guo L, et al
    An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation.
    Transl Androl Urol. 2026;15:341.
    PubMed         Abstract available
    
    
62. HU J, Wang Y, Du Y, Li X, et al
    SESN2 promotes ferroptosis in bladder cancer by negatively regulating the NRF2/FSP1 signaling axis.
    Transl Androl Urol. 2026;15:332.
    PubMed         Abstract available
    
    

    
    Transl Oncol

63. PAN B, Zheng J, Luo Z, Hou S, et al
    Single-cell and spatial transcriptomics reveal a DLL4-associated tip-like endothelial niche linked to neoadjuvant chemotherapy non-response in muscle-invasive bladder cancer.
    Transl Oncol. 2026;74:103067.
    PubMed         Abstract available
    
    

    
    Urol Oncol

64. KLUGMAN Y, Cordero NM, Harrington G, Khan M, et al
    Impact of second-look TURBT on high grade recurrence and intravesical therapy in high-risk non-muscle-invasive bladder cancer: A 20-year experience.
    Urol Oncol. 2026 Oct 10:S1078-1439(26)00737.
    PubMed         Abstract available
    
    
65. SAFARINEJAD MR, Safarinejad S, Shafiei N, Safarinejad S, et al
    Retraction notice to "Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility" [Urologic Oncology: Seminars and Original Investigations 31 (2013) 1193-1203].
    Urol Oncol. 2026 Oct 12:S1078-1439(26)00701.
    PubMed        
    
    
66. KOHLER J, Rodler S
    Response to "Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival".
    Urol Oncol. 2026 Oct 13:S1078-1439(26)00746.
    PubMed        
    
    
67. NANJO GU, Fu Z, Smani S, Lokeshwar SD, et al
    Translational research models for variant subtype bladder cancers: A comprehensive review of the current landscape.
    Urol Oncol. 2026 Oct 13:S1078-1439(26)00735.
    PubMed         Abstract available
    
    
68. SUBIELA JD, Gonzalez-Padilla DA, Scilipoti P, Slusarczyk A, et al
    Perioperative enfortumab vedotin-pembrolizumab, gemcitabine-cisplatin-durvalumab, and dose-dense MVAC in cisplatin-eligible muscle-invasive bladder cancer: A benefit-risk Bayesian network meta-analysis.
    Urol Oncol. 2026 Sep 22:S1078-1439(26)00738.
    PubMed         Abstract available
    
    
69. SHELDON J, Holt S, Brewer E, Gore JL, et al
    Prospectively collected functional vs. self-reported frailty measures and postoperative outcomes after radical cystectomy in older adults with bladder cancer.
    Urol Oncol. 2026 Oct 16:S1078-1439(26)00736.
    PubMed         Abstract available
    
    

    
    Urology

70. ERGAS IJ, Zimbalist A, Haque R, Lee VS, et al
    Diet quality and prognosis in patients with non-muscle invasive bladder cancer: the Be-Well Study.
    Urology. 2026 Oct 15:S0090-4295(26)00668-0. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

    
    Xenotransplantation

71. SHYR CR, Shih CK, Wu CF, Ma WL, et al
    In Vitro and In Vivo Characterization of Porcine Urothelial Cells as an Intravesical Cellular Xenotransplantation Immunotherapeutic Agent for Bladder Cancer.
    Xenotransplantation. 2026;33:e70167.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum